Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imdusiran + durvalumab
- Development stage
- Unknown
- Lead developer
- Arbutus Biopharma
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
**Imdusiran + durvalumab** is a combination investigational therapy being studied for the treatment of chronic hepatitis B virus (HBV) infection. Imdusiran (code name AB-729) is a small interfering RNA (siRNA) antiviral that directly targets HBV RNA, aiming to suppress the expression of viral proteins and reduce viral load. Durvalumab (brand name Imfinzi, code name MEDI4736) is a fully human monoclonal antibody targeting programmed death-ligand 1 (PD-L1). Durvalumab functions as an immune checkpoint inhibitor, enhancing T-cell mediated immune responses by blocking the interaction of PD-L1 with its receptors PD-1 and CD80, thus promoting immune recognition and activity against infected cells. The combination is designed to suppress viral activity with imdusiran while simultaneously augmenting the host immune response with durvalumab, with the goal of achieving a functional cure for HBV infection[1][3][5][7].
- Other names
- imdusiran + durvalumab
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on imdusiran + durvalumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imdusiran + durvalumab.